All Blogs / Industries / Medical / Pharmaceutical / New


Chlorine Azide For Everyone

One of my "Things I Won't Work With" compounds may have moved into a zone where I'd actually use it. This new paper in JOC describes in situ preparation of small amounts of chlorine azide, which can then react with alkene to give useful beta-chloro azide products. Show More Summary

Of Proteasome Inhibitors and PAINs

Amgen is out with some new data that might well justify their purchase of Onyx a year and a half ago. A big driver for that deal was the proteasome inhibitor Kyprolis (carfilzomib), and the company just reported results in a head-to-head...Show More Summary

Gene Editing Therapies Thunder Along

Here's a one-stop way to get caught up with all the therapeutic gene editing technologies out there, courtesy of Nature Medicine. Huge amounts of money are flowing into this area, because CRISPR/Cas9 looks so solid, compared to the various other things that have been tried in the past. Show More Summary

IIR's 7th Annual Government Programs Summit

This is the Only Government Programs Event You Need to AttendHow many Government Programs events do you attend a year? IT ONLY HAS TO BE THIS ONE! IIR's 7th Annual Government Programs Summit on March 23-25, 2015 in Arlington is the one-stop-shop...Show More Summary

Weekly Roundup 2.27.15

Another round of snow this week, perhaps the last gasp of winter? I can’t say there is any hint of Spring in the air in these parts, but sure hope there is where you are. In any event, I am … Continue reading ?

PAINs And Good Old Med Chem

The mainstreaming of the PAINs concept continues, with editorials from Jonathan Baell in ACS Med. Chem. Letters and Dan Erlanson in J. Med. Chem.. Both are definitely worth a read. Baell emphasizes that real hits tend to have real SAR around them. Show More Summary

AZ Spins Off Anti-Infectives

Word came yesterday that AstraZeneca is spinning off its anti-infectives division into a separate subsidiary company. This does not appear to have been their first choice - they've been shopping these assets around for actual cash, but had no takers (at least, on their terms). Show More Summary

Building a Strong Pharma Sales Approach in the New ACO Marketplace

Today’s guest post comes from two physician-leaders of major accountable care organizations (ACOs): Anthony Slonim, MD, DrPH, CPE, FACPE; President and CEO of Renown Health, Reno, NV; Chair, CMR Institute’s Board of Directors Jeffrey...Show More Summary

A KOL By Any Other Name Would Smell As Sour

Nearly two-thirds (62%) of medical experts (physicians who could be deemed genuine experts) believe the pharmaceutical industry should replace the term Key Opinion Leader (KOL) – according to the results of a new international online survey to be presented today at the Medical Affairs Leaders Forum in Berlin, Germany. Show More Summary

Ibrutinib's Rise

Pharmacyclics and their reactive kinase inhibitor Imbruvica (ibrutinib) have come up a few times around here in the past. (And someone who was involved in its earlier development at Celera shows up here in the comments from time to time). Show More Summary

Double-Blinded Peer Review

Nature has decided to add an option for double-blind peer review - papers would be sent to the referees without author names or institutional affiliation on them. I think this is a worthwhile idea, but I agree with many of the points...Show More Summary

The Latest Fragment List

Practical Fragments has an updated list of all the drug that have made it into the clinic from fragment-based drug design. There are more than thirty of them, and there are probably more that aren't on the list yet. So while fragment-based...Show More Summary

News Roundup, February 2014: CVS Health, Walgreens Boots Alliance, Celgene, 340B, and more

Brrrr! This year’s ultra-cold winter is not done yet. (I blame Elsa.) To stay warm, please enjoy this month's look at noteworthy new stories from the Drug Channels universe. In this issue: CVS Health prepares you for the next specialty...Show More Summary

Legislative Proposals in the 114th Congress

Every so often, EyeonFDA has an update for you on legislation that is proposed in the Congress that would impact the medical product marketplace if passed.  The new Congress has just two months old and while the last Congress was … Continue reading ?

Lack of Adherence: A Haiku for Pharma

HealthPrize, a company that offers rewards to patients who take their medications, challenged ePharma Summit attendees and Twitter followers (hashtag: #epharma) to a Haiku contest. The challenge is to write a Haiku - a 17-syllable verse form consisting of three metrical units (lines) of 5, 7, and 5 syllables. Show More Summary

All That Cash

From the LifeSciVC blog, here's a revealing comparison of the amount of money going into startups in this business. This is why I tend to get worked up about the number of stock buyback plans among the big pharma players. It would seem...Show More Summary

Impact of mHealth on Adherence and Patient Outcomes Needs Improving. How "Open, Crowdsourced" Data from Pharma Can Help

A study just published in the Journal of Medical Internet Research (JMIR) concludes that "there is potential for mHealth tools to better facilitate adherence to chronic disease management, but the evidence supporting its current effectiveness is mixed. Show More Summary

I'm a Pundit, Yes I Am!

Andrew Spong, a pundit writing for STweM blog, just dissed pundits in an opinion piece titled "Pundits, prognosticators, philosophers, and practitioners: the exotic species of the health conversation on the social web." "In additionShow More Summary

CMS to Part D Preferred Pharmacy Networks: We’ll Be Watching You

This past Friday, the Centers for Medicaid & Medicare Services (CMS) released its thoroughly-titled Advance Notice of Methodological Changes for Calendar Year (CY) 2016 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2016 Call Letter. Show More Summary

An Antibiotic Discovery Prize

Ezekiel Emanuel of the University of Pennsylvania has a proposal in the New York Times for a prize in antibiotic discovery: Let’s use prize money. What if the United States government — maybe in cooperation with the European Union and...Show More Summary

Copyright © 2015 Regator, LLC